UCB's Global Corporate Website
Welcome to UCB in the United States
  • Healthcare Professionals
  • Patients
  • Investors

    • Categories

    Archives

    Sep

    30

    UCB Announces a Head-to-Head Study Evaluating BIMZELX® (bimekizumab) versus SKYRIZI® (risankizumab) in Active Psoriatic Arthritis

    Read More Share:linkedin| twitter| email

    Sep

    27

    UCB Announces Late-Breaking Two-Year Data for BIMZELX® (bimekizumab-bkzx) in Moderate-to-Severe Hidradenitis Suppurativa at EADV 2024

    Read More Share:linkedin| twitter| email

    Sep

    25

    UCB Presents New 4-year Data for BIMZELX® (bimekizumab-bkzx) in Moderate-to-Severe Plaque Psoriasis at EADV 2024

    Read More Share:linkedin| twitter| email

    Sep

    23

    UCB Announces U.S. FDA Approvals for BIMZELX® (bimekizumab-bkzx) for the Treatment of Psoriatic Arthritis, Non-radiographic Axial Spondyloarthritis, and Ankylosing Spondylitis

    Read More Share:linkedin| twitter| email

    Sep

    23

    Redefining Immunology Care: Our Pledge to Patients and the Healthcare Community

    Read More Share:linkedin| twitter| email

    Sep

    09

    TK2d Awareness Day: The complexity of this rare, genetic mitochondrial disease and its impact on daily living can no longer be overlooked

    Read More Share:linkedin| twitter| email

    Sep

    05

    The Legacy Continues: Celebrating Two Decades of the UCB Family Epilepsy Scholarship ProgramTM

    Read More Share:linkedin| twitter| email

    © 2009 - 2020 UCB, Inc., Atlanta. All rights reserved.
    USPR-CORP-0115-00003(2)